Skip to main content

ASCIA News

  • Activity based funding for subcutaneous immunoglobulin (SCIg) therapy
    The Independent Health and Aged Care Pricing Authority has announced Activity Based Funding (ABF) from 1 July 2024 for home delivered subcutaneous immunoglobulin (SCIg) infusion therapy.(2.11) in its Tier 2 Non-Admitted Services Compendium 2024–2025. This means that SCIg...
  • Product Update - Anapen® Adrenaline (Epinephrine) Injector Devices
    Arrotex Pharmaceuticals has advised that the sale and distribution of Anapen® Junior 150 and Anapen® 300 adrenaline (epinephrine) injector devices, used for the emergency treatment of anaphylaxis are to cease in Australia: Anapen® 300 will be available until end July 2024. Anapen®...
  • New Australian Hereditary Angioedema (HAE) publication
    A study on hereditary angioedema (HAE) prevalence and satisfaction with prophylaxis in South Australia has been published in the World Allergy Organization Journal (2024) 17:100918 http://doi.org/10.1016/j.waojou.2024.100918 by Alexander Troelnikov, Karen Milburn, Pravin...
  • TGA Consultation - Proposed Reforms to Therapeutic Goods Regulations
    The Therapeutic Goods Administration (TGA) is seeking public comment on proposed reforms to Part 5 of the Therapeutic Goods Regulations 1990. The proposed reforms are aimed at strengthening and modernising the legislative framework for the examination, testing and analysis...
  • Update on Alfamino® Infant Formula PBS and Pharmac listings - 1 August 2024
    Nestlé Health Science has informed ASCIA that only the updated recipe of Alfamino® amino acid formula for infants will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 August 2024. Since 1 September 2023, both the newer and older recipe Alfamino® products...
  • Alfaré® infant formula to be deleted from PBS - 1 August 2024
    Nestlé Health Science has informed ASCIA that supply of Alfaré® extensively hydrolysed infant formula (400g) is being discontinued in Australia and will be deleted from the Pharmaceutical Benefits Scheme (PBS) on 1 August 2024. There will be a supply only period, which...
  • Updated ASCIA Adrenaline Device PBS Authority Form
    ASCIA recommends the use of adrenaline (epinephrine) as the first line emergency/first aid treatment for severe allergic reactions (anaphylaxis) using either of the following two brands of adrenaline injector devices, EpiPen® or Anapen®, which are both available in...
  • ASCIA 2024 Conference registration is still open
    Registration is still open for the ASCIA 2024 Conference at https://ascia2024.com/registration To date there are 455 registered delegates (80% in person), a sold out exhibition and more than 150 abstracts have been received for posters and clinical grand rounds. Authors will...
ASCIA Member Login

Site last updated: 11 Jun 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...